Addressing Safety Concerns and Mitigating Toxicities in EGFR-Mutated NSCLC

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, explore proactive and reactive strategies to manage adverse effects associated with frontline EGFR-directed regimens in non–small cell lung cancer. Spira discusses prophylaxis measures and monitoring approaches to mitigate infusion-related reactions, dermatologic toxicities, and other class-specific effects. Raez outlines dose modification strategies and supportive care interventions aimed at maintaining treatment intensity while preserving quality of life.